Abstract
Circulating tumor DNA (ctDNA) from blood plasma has emerged as a promising biomarker for noninvasive profiling of tumor mutational landscapes and disease monitoring across cancers. In this study, we developed a targeted next-generation sequencing approach to explore the role of ctDNA for comprehensive tumor genotyping, early response prediction, and characterization of clonal heterogeneity in patients with advanced and rare cancers treated within molecular tumor boards. We applied our technology to 157 plasma specimens from 57 patients at distinct disease milestones and detected tumor variants in 96% of baseline samples, with 65% of them harboring actionable aberrations. Longitudinal monitoring of baseline mutations in on-treatment plasma revealed that ctDNA dynamics were significantly associated with clinical outcomes and enabled early prediction of disease progression. Finally, we observed substantial clonal heterogeneity over time, identifying emerging mutations in all analyzed plasma samples obtained at progression, including potentially targetable variants for subsequent personalized therapies.
Competing Interest Statement
L.R. does not report any conflicts of interest. J.C.K. does not report any conflicts of interest. F.S. receives research funding from Gilead Sciences, Roche Sequencing Solutions, and Takeda, and received Honoraria by AstraZeneca and Servier. F.M. is co-investor on patents related to cell-free DNA analysis. He has consulted for Roche Dx. He has support from Biomodal. Any other authors do not report any conflicts of interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the University Medical Center Freiburg gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Funder Information Declared
